ANT308
Cancer
Pre-clinicalActive
Key Facts
About Cambium Oncology
Cambium Oncology is pioneering a novel class of immunotherapies targeting the VIP/VPAC axis, an immunosuppressive pathway exploited by cancer cells. Its lead candidate, CAMV-01, is a VIP antagonist designed to re-activate cytotoxic T-cells, with a pipeline that includes small molecules, cell therapies, and long-acting constructs. Founded on IP from Emory University and led by a seasoned team, the company employs a biomarker-driven, combination-focused strategy to de-risk development in a high-value oncology market. Cambium is a private, pre-revenue company advancing its programs through preclinical and early clinical development.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |